NEW YORK (GenomeWeb) – Adaptive Biotechnologies today announced that it has completed a $195 million Series F financing round.
Matrix Capital Management led the round, which included other new investors Senator Investment Group, Tiger Management, Rock Springs Capital, and an unnamed large healthcare investor. The firm also raised money from existing investors Viking Global Investors, Casdin Capital, and Alexandria Real Estate Equities.
The firm said it would use the proceeds to expand research and development, support commercialization of a biomarker identification technology for T-cell therapies, and fund regulatory submissions.
Adaptive Biotechnologies is creating a platform for next-generation sequencing of T cell and B cell receptors and a database for immune biomarkers to identify targets for use in immunotherapies.
In January, Adaptive Biotechnologies acquired immune sequencing firm Sequenta. The Fred Hutchinson Cancer Research Center spinout had previously raised a total of $120 million, with at least $105 million from Viking Global.